Navigation Links
Antibiotic may prove beneficial to preterm infant lung health
Date:4/25/2011

LEXINGTON, Ky. (April 26, 2011) A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia (BPD).

The study, published in Pediatric Pulmonology, showed subjects colonized or infected with the Ureaplasma bacteria developed BPD or died 73 percent of the time in the azithromycin-treated group, compared to 94 percent of the time in the placebo group.

Bronchopulmonary dysplasia is a chronic lung disorder characterized by inflammation and scarring in the lungs. It is common among premature infants, whose lungs are not fully developed before birth.

This disorder can lead to chronic lung damage or death. Many infants who survive are at a greater risk for having recurrent respiratory infections, such as pneumonia or bronchiolitis.

The presence of the Ureaplasma bacterium is a risk factor in developing BPD. This bacterium causes inflammation in the lungs and can also lead to meningitis, pneumonia or septicemia. It is passed on from mother to child. An estimated 80 percent of women are already colonized with it, and nearly 45 percent of extremely preterm infants are affected by it.

"Current preventative therapies for bronchopulmonary dysplasia are limited," said Dr. Hubert O. Ballard, the UK neonatologist leading the study. "Because the inflammation from a Ureaplasma infection often leads to BPD, and because this bacterium is so easily spread to infants from the mother, we sought to find out if the anti-inflammatory benefits of azithromycin could help prevent the disorder from developing."

The study was performed on a group of 220 infants admitted to the UK Neonatal Intensive Care Unit from September 2004 to August 2008. Enrollment criteria included a birth weight of less than 1,250 grams, the use of intermittent mechanical ventilation for fewer than 12 hours, and an age of under 72 hours.

Upon enrollment, each infact was randomized to receive azithromycin or a placebo for a total of six weeks. Infants testing positive for Ureaplasma were placed in a separate subgroup of the study.

Ballard, et al, previously published a pilot study that demonstrated a possible benefit of azithromycin prophylaxis in infants weighing less than 1,000 grams, but the original study excluded patients who tested positive for the Ureaplasma bacteria.

Neither the previous study nor the current study demonstrated a statistically significant benefit to using azithromycin therapy to prevent BPD in preterm infants who were not colonized or infected with Ureasplasma.

Though the results of the study show potential for preventing bronchopulmonary dysplasia in Ureaplasma-colonized or infected patients, Dr. Ballard stressed that a larger multi-centered trial is needed to properly assess the benefits of azithromycin for these subjects.

"Our research demonstrates the benefit of treating preterm infants with azithromycin who are colonized or infected with Ureaplasma. To date, this is the largest single-center study to evaluate azithromycin use in preterm infants," Ballard said. "However, further studies are required to evaluate azithromycin therapy for the routine treatment of Ureaplasma colonization/infection in the preterm population."


'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-257-1754 x225
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Acne Antibiotics Not Linked to Drug Resistance
2. Antibiotic resistance spreads rapidly between bacteria
3. Lifesaving antibiotics face doubtful future
4. Antibiotic-Resistant Bacteria in India Could Spread, Experts Say
5. Research Warns of Overuse of Powerful Class of Antibiotics
6. For Young Kids With Pneumonia, Timing of Antibiotic Critical: Study
7. When you cough up green or yellow phlegm you need to be prescribed antibiotics, right?
8. Careful cleaning of childrens skin wounds key to healing, regardless of antibiotic choice
9. New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection
10. Some Antibiotics, Blood Pressure Meds a Bad Mix: Study
11. Predatory Bacteria May Help Control Antibiotic-Resistant Germs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: